ADVICENNE (PROM.) EO-,20 Logo
FR0013296746
A2H8SU
ALDVI.PA

ADVICENNE (PROM.) EO-,20

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, ADVICENNE (PROM.) EO-,20 had revenue of €2.88m and net profit of €4.62m

(EUR) June 2026
YoY
Revenue 2.88m -
Gross profit -3.03m -
Net profit 4.62m -
EBITDA 5.88m -

Fundamentals

Metric Value
Market capitalization
€9.17m
Number of shares
14.55m
52-week high/low
€2.35 - €0.61
Dividends No
Beta
0.96
P/E ratio
211.43
PEG ratio
2.11
P/B ratio
-0.42
P/S ratio
1.63

Company profile

Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.

Name
ADVICENNE (PROM.) EO-,20
CEO
Didier Laurens
Headquarters Paris, if
France
Website
IPO
06/12/2017
Employees 11

Ticker symbols

Exchange Symbol
Euronext
ALDVI.PA
Euronext
ADVIC.PA
Frankfurt
3MM.F
Paris
ALDVI.PA
München
3MM.MU
Düsseldorf
3MM.DU
🍪

Parqet  uses cookies. Learn more